Helicon-enabled alpha radioligand therapies
Disease Need
Radiopharmaceuticals are an area of immense potential promise in cancer treatment. By specifically targeting cancer cells that express certain receptors or antigens, radiopharmaceuticals deliver radiation directly to the tumor while sparing surrounding healthy tissue, potentially reducing side effects compared to more conventional treatments like chemotherapy or external beam radiation. Clinical studies have shown radiopharmaceuticals’ power as a targeted cancer therapy surpasses even that of antibody-drug conjugates.
Our Approach
In collaboration with ARTBIO we are co-developing Helicon-enabled alpha-radioligand therapeutics (HEARTs) against multiple targets as new treatment options for patients with cancer. HEARTs will leverage our field-leading Helicon platform of tunable stabilized alpha-helical peptides and ARTBIO’s AlphaDirect™ platform for the development of alpha-radioligand therapeutics using the potential best-in-class isotope lead-212 (also called 212Pb). HEARTs with lead-212 have the ideal clinical profile due to a short half-life that delivers maximal energy into tumors with high stability and the ability to image with SPECT/CT. The synergy of these two powerful platforms offers promising potential to create next-generation alpha-radioligand therapeutics with properties ideal for precise delivery to tumors.